|
|
Article: Once-weekly exenatide lowers glycemia, weight.(News)
- Article from:
- Internal Medicine News
- Article date:
- August 1, 2008
- Author:
CopyrightCOPYRIGHT 2008 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN FRANCISCO--An investigational once-weekly formulation of exenatide resulted in superior improvements in glucose control at 30 weeks, compared with the current twice-daily version, and clicited sustained glycemic control and weight loss at 1 year in patients with type 2 diabetes.
The phase III data were presented in two separate sessions at the annual scientific sessions of the American Diabetes Association. The twice-daily injectable in-cretin mimetic is comarketed as Byetta by Amylin Pharmaceuticals Inc., Eli Lilly & Co., and Alkermes Inc. An application for approval of the long-acting release formulation was filed with the Food and Drug Administration in ...
Related newspaper, magazine, and journal articles:
|
|
Article: Weekly group aims to help divorced, separated and ...
Northwest Florida Daily News (Fort Walton Beach, FL);
October 7, 2006 ;
627 words
...Oct. 7--Divorced, separated and widowed individuals are invited to Recovery in Progress, a weekly social discussion group that will meet from 10 a.m. until noon, starting Friday at Christ Our Redeemer Catholic Church in Niceville. Certified facilitator Ann Garrett will lead the meetings. Garrett
|
|